These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

529 related articles for article (PubMed ID: 14565644)

  • 1. Cytokine-induced killer cells: NK-like T cells with cytotolytic specificity against leukemia.
    Linn YC; Hui KM
    Leuk Lymphoma; 2003 Sep; 44(9):1457-62. PubMed ID: 14565644
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expansion of Philadelphia chromosome-negative CD3(+)CD56(+) cytotoxic cells from chronic myeloid leukemia patients: in vitro and in vivo efficacy in severe combined immunodeficiency disease mice.
    Hoyle C; Bangs CD; Chang P; Kamel O; Mehta B; Negrin RS
    Blood; 1998 Nov; 92(9):3318-27. PubMed ID: 9787169
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expansion of cytotoxic CD3+ CD56+ cells from peripheral blood progenitor cells of patients undergoing autologous hematopoietic cell transplantation.
    Alvarnas JC; Linn YC; Hope EG; Negrin RS
    Biol Blood Marrow Transplant; 2001; 7(4):216-22. PubMed ID: 11349808
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization of the recognition and functional heterogeneity exhibited by cytokine-induced killer cell subsets against acute myeloid leukaemia target cell.
    Linn YC; Lau SK; Liu BH; Ng LH; Yong HX; Hui KM
    Immunology; 2009 Mar; 126(3):423-35. PubMed ID: 18778291
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chimeric antigen receptor-engineered cytokine-induced killer cells overcome treatment resistance of pre-B-cell acute lymphoblastic leukemia and enhance survival.
    Oelsner S; Wagner J; Friede ME; Pfirrmann V; Genßler S; Rettinger E; Buchholz CJ; Pfeifer H; Schubert R; Ottmann OG; Ullrich E; Bader P; Wels WS
    Int J Cancer; 2016 Oct; 139(8):1799-809. PubMed ID: 27253354
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dual-functional capability of CD3+CD56+ CIK cells, a T-cell subset that acquires NK function and retains TCR-mediated specific cytotoxicity.
    Pievani A; Borleri G; Pende D; Moretta L; Rambaldi A; Golay J; Introna M
    Blood; 2011 Sep; 118(12):3301-10. PubMed ID: 21821703
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The dual-functional capability of cytokine-induced killer cells and application in tumor immunology.
    Zhang Q; Liu XY; Zhang T; Zhang XF; Zhao L; Long F; Liu ZK; Wang EH
    Hum Immunol; 2015 May; 76(5):385-91. PubMed ID: 25305457
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The cytotoxic potential of interleukin-15-stimulated cytokine-induced killer cells against leukemia cells.
    Rettinger E; Kuçi S; Naumann I; Becker P; Kreyenberg H; Anzaghe M; Willasch A; Koehl U; Bug G; Ruthardt M; Klingebiel T; Fulda S; Bader P
    Cytotherapy; 2012 Jan; 14(1):91-103. PubMed ID: 21973023
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A novel population of expanded human CD3+CD56+ cells derived from T cells with potent in vivo antitumor activity in mice with severe combined immunodeficiency.
    Lu PH; Negrin RS
    J Immunol; 1994 Aug; 153(4):1687-96. PubMed ID: 7519209
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Can the dual-functional capability of CIK cells be used to improve antitumor effects?
    Wang X; Yu W; Li H; Yu J; Zhang X; Ren X; Cao S
    Cell Immunol; 2014 Jan; 287(1):18-22. PubMed ID: 24355711
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Generation of cytokine-induced killer cells from leukaemic samples with in vitro cytotoxicity against autologous and allogeneic leukaemic blasts.
    Linn YC; Lau LC; Hui KM
    Br J Haematol; 2002 Jan; 116(1):78-86. PubMed ID: 11841399
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase I/II clinical trial of autologous cytokine-induced killer cells as adjuvant immunotherapy for acute and chronic myeloid leukemia in clinical remission.
    Linn YC; Yong HX; Niam M; Lim TJ; Chu S; Choong A; Chuah C; Goh YT; Hwang W; Loh Y; Ng HJ; Suck G; Chan M; Koh M
    Cytotherapy; 2012 Aug; 14(7):851-9. PubMed ID: 22799277
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Significance of Frequencies, Compositions, and/or Antileukemic Activity of (DC-stimulated) Invariant NKT, NK and CIK Cells on the Outcome of Patients With AML, ALL and CLL.
    Boeck CL; Amberger DC; Doraneh-Gard F; Sutanto W; Guenther T; Schmohl J; Schuster F; Salih H; Babor F; Borkhardt A; Schmetzer H
    J Immunother; 2017; 40(6):224-248. PubMed ID: 28557814
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Generation of CD3+ CD56+ cytokine-induced killer cells and their in vitro cytotoxicity against pediatric cancer cells.
    Hongeng S; Petvises S; Worapongpaiboon S; Rerkamnuaychoke B; Pakakasama S; Jootar S
    Int J Hematol; 2003 Feb; 77(2):175-9. PubMed ID: 12627854
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bone marrow mesenchymal stem cells reduce the antitumor activity of cytokine-induced killer/natural killer cells in K562 NOD/SCID mice.
    Li Y; Qu YH; Wu YF; Wang XP; Wei J; Huang WG; Zhou DH; Fang J; Huang K; Huang SL
    Ann Hematol; 2011 Aug; 90(8):873-85. PubMed ID: 21234566
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Activated natural killer cells from patients with acute myeloid leukemia are cytotoxic against autologous leukemic blasts in NOD/SCID mice.
    Siegler U; Kalberer CP; Nowbakht P; Sendelov S; Meyer-Monard S; Wodnar-Filipowicz A
    Leukemia; 2005 Dec; 19(12):2215-22. PubMed ID: 16224486
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Human interferon-alpha increases the cytotoxic effect of CD56(+) cord blood-derived cytokine-induced killer cells on human B-acute lymphoblastic leukemia cell lines.
    Durrieu L; Gregoire-Gauthier J; Dieng MM; Fontaine F; le Deist F; Haddad E
    Cytotherapy; 2012 Nov; 14(10):1245-57. PubMed ID: 22974386
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A new method for in vitro expansion of cytotoxic human CD3-CD56+ natural killer cells.
    Carlens S; Gilljam M; Chambers BJ; Aschan J; Guven H; Ljunggren HG; Christensson B; Dilber MS
    Hum Immunol; 2001 Oct; 62(10):1092-8. PubMed ID: 11600215
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cytotoxicity of cytokine-induced killer cells coated with bispecific antibody against acute myeloid leukemia cells.
    Kaneko T; Fusauch Y; Kakui Y; Okumura K; Mizoguchi H; Oshimi K
    Leuk Lymphoma; 1994 Jul; 14(3-4):219-29. PubMed ID: 7950910
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Autologous cytokine-induced killer cell therapy in clinical trial phase I is safe in patients with primary hepatocellular carcinoma.
    Shi M; Zhang B; Tang ZR; Lei ZY; Wang HF; Feng YY; Fan ZP; Xu DP; Wang FS
    World J Gastroenterol; 2004 Apr; 10(8):1146-51. PubMed ID: 15069715
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.